181 related articles for article (PubMed ID: 32923146)
1. The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.
Barone M; Catani L; Ricci F; Romano M; Forte D; Auteri G; Bartoletti D; Ottaviani E; Tazzari PL; Vianelli N; Cavo M; Palandri F
Oncoimmunology; 2020 Jun; 9(1):1782575. PubMed ID: 32923146
[TBL] [Abstract][Full Text] [Related]
2. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
3. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.
Fisher DAC; Miner CA; Engle EK; Hu H; Collins TB; Zhou A; Allen MJ; Malkova ON; Oh ST
Leukemia; 2019 Aug; 33(8):1978-1995. PubMed ID: 30718771
[TBL] [Abstract][Full Text] [Related]
4. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Masarova L; Bose P; Pemmaraju N; Zhou L; Pierce S; Estrov Z; Kantarjian H; Verstovsek S
Acta Haematol; 2023; 146(6):522-529. PubMed ID: 37699357
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.
Copher R; Kee A; Gerds A
Oncologist; 2022 Mar; 27(3):228-235. PubMed ID: 35274711
[TBL] [Abstract][Full Text] [Related]
6.
Glaser K; Silwedel C; Fehrholz M; Waaga-Gasser AM; Henrich B; Claus H; Speer CP
Front Cell Infect Microbiol; 2017; 7():484. PubMed ID: 29234642
[No Abstract] [Full Text] [Related]
7. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Palumbo GA; Breccia M
Cancer; 2022 Jul; 128(13):2449-2454. PubMed ID: 35363892
[TBL] [Abstract][Full Text] [Related]
8. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
[No Abstract] [Full Text] [Related]
9. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
10. AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
Duminuco A; Mosquera-Orgueira A; Nardo A; Di Raimondo F; Palumbo GA
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1881. PubMed ID: 37553891
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of prenylated stilbenoid macasiamenene F through its anti-inflammatory and cytoprotective effects on LPS-challenged monocytes and microglia.
Leláková V; Béraud-Dufour S; Hošek J; Šmejkal K; Prachyawarakorn V; Pailee P; Widmann C; Václavík J; Coppola T; Mazella J; Blondeau N; Heurteaux C
J Ethnopharmacol; 2020 Dec; 263():113147. PubMed ID: 32736058
[TBL] [Abstract][Full Text] [Related]
12. Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation.
Matassoli FL; Leão IC; Bezerra BB; Pollard RB; Lütjohann D; Hildreth JEK; Arruda LB
mSphere; 2018 Nov; 3(6):. PubMed ID: 30404938
[TBL] [Abstract][Full Text] [Related]
13. Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.
Sollazzo D; Forte D; Polverelli N; Romano M; Perricone M; Rossi L; Ottaviani E; Luatti S; Martinelli G; Vianelli N; Cavo M; Palandri F; Catani L
Oncotarget; 2016 Jul; 7(28):43974-43988. PubMed ID: 27304059
[TBL] [Abstract][Full Text] [Related]
14. Impaired mitogen-activated protein kinase activation and altered cytokine secretion in endotoxin-tolerant human monocytes.
Heagy W; Hansen C; Nieman K; Rodriguez JL; West MA
J Trauma; 2000 Nov; 49(5):806-14. PubMed ID: 11086768
[TBL] [Abstract][Full Text] [Related]
15. Increased SLAMF7
Maekawa T; Kato S; Kawamura T; Takada K; Sone T; Ogata H; Saito K; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Horiuchi T; Hikota-Saga R; Endo-Umeda K; Uno S; Osawa Y; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Usuki K; Morishita S; Araki M; Makishima M; Komatsu N; Kimura F
Blood; 2019 Sep; 134(10):814-825. PubMed ID: 31270105
[TBL] [Abstract][Full Text] [Related]
16. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis.
Wanidworanun C; Strober W
J Immunol; 1993 Dec; 151(12):6853-61. PubMed ID: 8258695
[TBL] [Abstract][Full Text] [Related]
17. Intracellular monocyte cytokine production and CD 14 expression are up-regulated in severe vs mild chronic heart failure.
Conraads VM; Bosmans JM; Schuerwegh AJ; Goovaerts I; De Clerck LS; Stevens WJ; Bridts CH; Vrints CJ
J Heart Lung Transplant; 2005 Jul; 24(7):854-9. PubMed ID: 15982613
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 effects on activated monocytes lead to novel cytokine secretion profiles intermediate between those induced by interleukin-10 and by interferon-gamma.
Minty A; Ferrara P; Caput D
Eur Cytokine Netw; 1997 Jun; 8(2):189-201. PubMed ID: 9262968
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.
Masarova L; Bose P; Pemmaraju N; Daver N; Zhou L; Pierce S; Kantarjian H; Estrov Z; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):318-327.e6. PubMed ID: 33551345
[TBL] [Abstract][Full Text] [Related]
20. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis.
Sebbag M; Parry SL; Brennan FM; Feldmann M
Eur J Immunol; 1997 Mar; 27(3):624-32. PubMed ID: 9079801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
